Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OnabotulinumtoxinA in poststroke upper limb spasticity
NCT02145689Phase 3Withdrawn
- Sponsor
- Allergan
- Start
- Aug 2014
- Primary completion
- May 2017
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of onabotulinumtoxinA in Spasticity, sponsored by Allergan. Planned start Aug 2014; status: withdrawn.
02
Drugs
onabotulinumtoxinA
03
Conditions
Spasticity
Beyond the preview
Go deeper on NCT02145689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02145689.